Literature DB >> 24723492

The physical association of the P2Y12 receptor with PAR4 regulates arrestin-mediated Akt activation.

Aasma Khan1, Dongjun Li1, Salam Ibrahim1, Emer Smyth1, Donna S Woulfe2.   

Abstract

It is now well accepted that protease activated receptor (PAR) 1 and PAR4 have differential roles in platelet activation. PAR4, a low-affinity thrombin receptor in human platelets, participates in sustained platelet activation in a P2Y12-dependent manner; however, the mechanisms are not defined. Our previous studies demonstrated that thrombin induces the association of PAR4 with P2Y12, together with arrestin recruitment to the complex. Here we show that PAR4 and P2Y12 directly interact to coregulate Akt signaling after PAR4 activation. We observed direct and specific interaction of P2Y12 with PAR4 but not PAR1 by bioluminescent resonance energy transfer when the receptors were coexpressed in human embryonic kidney 293T cells. PAR4-P2Y12 dimerization was promoted by PAR4-AP and inhibited by P2Y12 antagonist. By using sequence comparison of the transmembrane domains of PAR1 and PAR4, we designed a mutant form of PAR4, "PAR4SFT," by replacing LGL194-196 at the base of transmembrane domain 4 with the corresponding aligned PAR1 residues SFT 220-222. PAR4SFT supported only 8.74% of PAR4-P2Y12 interaction, abolishing P2Y12-dependent arrestin recruitment to PAR4 and Akt activation. Nonetheless, PAR4SFT still supported homodimerization with PAR4. PAR4SFT failed to induce a calcium flux when expressed independently; however, coexpression of increasing concentrations of PAR4SFT, together with PAR4 potentiated PAR4-mediated calcium flux, suggested that PAR4 act as homodimers to signal to Gq-coupled calcium responses. In conclusion, PAR4 LGL (194-196) governs agonist-dependent association of PAR4 with P2Y12 and contributes to Gq-coupled calcium responses. PAR4-P2Y12 association supports arrestin-mediated sustained signaling to Akt. Hence, PAR4-P2Y12 dimerization is likely to be important for the PAR4-P2Y12 dependent stabilization of platelet thrombi.
Copyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24723492      PMCID: PMC4054002          DOI: 10.1124/mol.114.091595

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  46 in total

Review 1.  Dimerization: an emerging concept for G protein-coupled receptor ontogeny and function.

Authors:  Stephane Angers; Ali Salahpour; Michel Bouvier
Journal:  Annu Rev Pharmacol Toxicol       Date:  2002       Impact factor: 13.820

Review 2.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

Review 3.  Dimerization of alpha1-adrenoceptors.

Authors:  G Milligan; J Pediani; M Fidock; J F López-Giménez
Journal:  Biochem Soc Trans       Date:  2004-11       Impact factor: 5.407

4.  Receptor heterodimerization leads to a switch in signaling: beta-arrestin2-mediated ERK activation by mu-delta opioid receptor heterodimers.

Authors:  Raphael Rozenfeld; Lakshmi A Devi
Journal:  FASEB J       Date:  2007-03-23       Impact factor: 5.191

5.  Mapping human protease-activated receptor 4 (PAR4) homodimer interface to transmembrane helix 4.

Authors:  María de la Fuente; Daniel N Noble; Sheetal Verma; Marvin T Nieman
Journal:  J Biol Chem       Date:  2012-02-08       Impact factor: 5.157

6.  Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs.

Authors:  C J Foster; D M Prosser; J M Agans; Y Zhai; M D Smith; J E Lachowicz; F L Zhang; E Gustafson; F J Monsma; M T Wiekowski; S J Abbondanzo; D N Cook; M L Bayne; S A Lira; M S Chintala
Journal:  J Clin Invest       Date:  2001-06       Impact factor: 14.808

7.  The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts.

Authors:  Pierre Savi; Jean-Luc Zachayus; Nathalie Delesque-Touchard; Catherine Labouret; Caroline Hervé; Marie-Françoise Uzabiaga; Jean-Marie Pereillo; Jean-Michel Culouscou; Françoise Bono; Pascual Ferrara; Jean-Marc Herbert
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-11       Impact factor: 11.205

8.  Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis.

Authors:  Andrew J Leger; Suzanne L Jacques; Jehangir Badar; Nicole C Kaneider; Claudia K Derian; Patricia Andrade-Gordon; Lidija Covic; Athan Kuliopulos
Journal:  Circulation       Date:  2006-02-27       Impact factor: 29.690

9.  Internalization and recycling of activated thrombin receptors.

Authors:  J A Hoxie; M Ahuja; E Belmonte; S Pizarro; R Parton; L F Brass
Journal:  J Biol Chem       Date:  1993-06-25       Impact factor: 5.157

10.  C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast.

Authors:  Desiree H Floyd; Adi Geva; Stephen P Bruinsma; Mark C Overton; Kendall J Blumer; Thomas J Baranski
Journal:  J Biol Chem       Date:  2003-06-30       Impact factor: 5.157

View more
  21 in total

Review 1.  New Concepts and Mechanisms of Platelet Activation Signaling.

Authors:  Brian Estevez; Xiaoping Du
Journal:  Physiology (Bethesda)       Date:  2017-03

2.  Protease-activated Receptor-4 Signaling and Trafficking Is Regulated by the Clathrin Adaptor Protein Complex-2 Independent of β-Arrestins.

Authors:  Thomas H Smith; Luisa J Coronel; Julia G Li; Michael R Dores; Marvin T Nieman; JoAnn Trejo
Journal:  J Biol Chem       Date:  2016-07-11       Impact factor: 5.157

Review 3.  Protease-activated receptors in hemostasis.

Authors:  Marvin T Nieman
Journal:  Blood       Date:  2016-04-28       Impact factor: 22.113

4.  Enhanced potency of prasugrel on protease-activated receptors following bivalirudin treatment for PCI as compared to clopidogrel.

Authors:  Carey Kimmelstiel; Ryan Stevenson; Nga Nguyen; Layla Van Doren; Ping Zhang; James Perkins; Navin K Kapur; Andrew Weintraub; Vilma Castaneda; Athan Kuliopulos; Lidija Covic
Journal:  Thromb Res       Date:  2019-02-13       Impact factor: 3.944

5.  Development and characterization of monoclonal antibodies against Protease Activated Receptor 4 (PAR4).

Authors:  Michele M Mumaw; Maria de la Fuente; Amal Arachiche; James K Wahl; Marvin T Nieman
Journal:  Thromb Res       Date:  2015-04-09       Impact factor: 3.944

6.  Protease-activated receptor-4 and purinergic receptor P2Y12 dimerize, co-internalize, and activate Akt signaling via endosomal recruitment of β-arrestin.

Authors:  Thomas H Smith; Julia G Li; Michael R Dores; JoAnn Trejo
Journal:  J Biol Chem       Date:  2017-06-26       Impact factor: 5.157

Review 7.  G Protein-Coupled Receptor Signaling Through β-Arrestin-Dependent Mechanisms.

Authors:  Pierre-Yves Jean-Charles; Suneet Kaur; Sudha K Shenoy
Journal:  J Cardiovasc Pharmacol       Date:  2017-09       Impact factor: 3.105

8.  Race differences in platelet reactivity: is protease activated receptor 4 a predictor of response to therapy?

Authors:  Michele M Mumaw; Marvin T Nieman
Journal:  Arterioscler Thromb Vasc Biol       Date:  2014-12       Impact factor: 8.311

9.  The protease-activated receptor 4 Ala120Thr variant alters platelet responsiveness to low-dose thrombin and protease-activated receptor 4 desensitization, and is blocked by non-competitive P2Y12 inhibition.

Authors:  M J Whitley; D M Henke; A Ghazi; M Nieman; M Stoller; L M Simon; E Chen; J Vesci; M Holinstat; S E McKenzie; C A Shaw; L C Edelstein; P F Bray
Journal:  J Thromb Haemost       Date:  2018-11-22       Impact factor: 5.824

10.  Targeting the anionic region of human protease-activated receptor 4 inhibits platelet aggregation and thrombosis without interfering with hemostasis.

Authors:  M M Mumaw; M de la Fuente; D N Noble; M T Nieman
Journal:  J Thromb Haemost       Date:  2014-06-27       Impact factor: 5.824

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.